synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-12. Anything still debated is marked as such rather than presented as settled.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Atrial natriuretic peptide (natriuretic polypeptide (ANP) or atrial natriuretic factor (ANF) is a natriuretic peptide hormone secreted from the cardiac atria that in humans is encoded by the NPPA gene. Natriuretic peptides (ANP, BNP, and CNP) are a family of hormone/paracrine factors that are structurally related. The main function of ANP is causing a reduction in expanded extracellular fluid (ECF) volume by increasing renal sodium excretion. ANP is synthesized and secreted by cardiac muscle cells in the walls of the atria in the heart. These cells contain volume receptors which respond to increased stretching of the atrial wall due to increased atrial blood volume. Reduction of blood volume by ANP can result in secondary effects such as reduction of extracellular fluid (ECF) volume, improved cardiac ejection fraction with resultant improved organ perfusion, decreased blood pressure, and increased serum potassium. These effects may be blunted or negated by various counter-regulatory mechanisms operating concurrently on each of these secondary effects. Brain natriuretic peptide (BNP) – a misnomer; it is secreted by cardiac muscle cells in the heart ventricles – is similar to ANP in its effect. It acts via the same receptors as ANP does, but with 10-fold lower affinity than ANP. The biological half-life of BNP, however, is twice as long as that of ANP, and that of NT-proBNP is even longer, making these peptides better choices than ANP for diagnostic blood testing.
=== Special populations === Globally, bromazepam is contraindicated and should be used with caution in women who are pregnant, the elderly, patients with a history of alcohol or other substance abuse disorders and children. In 1987, a team of scientists led by Ochs reported that the elimination half-life, peak serum concentration, and serum free fraction are significantly elevated and the oral clearance and volume of distribution significantly lowered in elderly subjects. The clinical consequence is that the elderly should be treated with lower doses than younger patients. Bromazepam may affect driving and ability to operate machinery. Bromazepam is pregnancy category D, a classification that means that bromazepam has been shown to cause harm to the unborn child. The Hoffman LaRoche product information leaflet warns against breast feeding while taking bromazepam. There has been at least one report of sudden infant death syndrome linked to breast feeding while consuming bromazepam.
Treosulfan, sold under the brand name Trecondi among others, is an alkylating medication given to people before they have a bone marrow transplant from a donor known as allogeneic hematopoietic stem cell transplantation. It is used as a 'conditioning' treatment to clear the bone marrow and make room for the transplanted bone marrow cells, which can then produce healthy blood cells. It is used together with another medicine called fludarabine in adults and children from one month of age with blood cancers as well as in adults with other severe disorders requiring a bone marrow transplant. It belongs to the family of drugs called alkylating agents. In the body, treosulfan is converted into other compounds called epoxides which kill cells, especially cells that develop rapidly such as bone marrow cells, by attaching to their DNA while they are dividing. DNA cross-linking is considered a primary mechanism underlying the pharmacological action of treosulfan, and epoxides formed from treosulfan may cross-link DNA via at least two chemical pathways. Preclinical studies in animal models have shown that treosulfan is widely distributed to the liver, lungs, bone marrow, and skeletal muscle, with tissue-to-plasma ratios of 0.96, 0.82, 0.82, and 0.77, respectively. Lower biodistribution was observed in the brain and the aqueous humor of the eye (both 0.10). In juvenile rats with an immature blood–brain barrier, brain exposure was higher (0.15) than in young adult rats.
Sources: en.wikipedia.org
=== Diabetes === Low IGF1 levels are shown to increase the risk of developing type 2 diabetes and insulin resistance. On the other hand, a high IGF1 bioavailability in people with diabetes may delay or prevent diabetes-associated complications, as it improves impaired small blood vessel function. IGF1 has been characterized as an insulin sensitizer. Low serum IGF1 levels can be considered an indicator of liver fibrosis in type 2 diabetes mellitus patients.
=== Non-surgical === Indicated for people with exposed bone with symptoms of infection. This treatment modality may also be utilised for patients with other co-morbidities which precludes invasive surgical methods. This approach requires antimicrobial mouthwashes, systemic antibiotics and antifungal medication and analgesics.
Top-icing is the practice of placing a 2-inch (51 mm) to 4-inch (100 mm) layer of crushed ice on top of agricultural products that have high respiration rates, need high relative humidity, and benefit from having the cooling agent sit directly atop the load (or within individual boxes). Cars with pre-cooled fresh produce were top-iced just before shipment. Top-icing added considerable dead weight to the load. Top-icing a 40-foot (12 m) reefer required in excess of 10,000 pounds (4,500 kg) of ice. It had been postulated that as the ice melted, the resulting chilled water would trickle down through the load, continuing the cooling process. It was found, however, that top-icing benefited only the uppermost layers of the cargo, and that the water from melting ice often passed through spaces between the cartons and pallets, with little or no cooling effect. It was ultimately determined that top-icing is useful only in preventing an increase in temperature and was eventually discontinued.
== History == "J.A. Folger & Co. were established in 1850 as Wm. H. Bovee & Co" The precursor of the Folger Coffee Company was founded in 1850 in San Francisco, California, as the Pioneer Steam Coffee and Spice Mills. Prior to that Californians had to purchase green coffee beans and roast and grind them on their own. The mill’s founding owner, William H. Bovee, saw the opportunity to produce roasted and ground coffee ready for brewing. Bovee hired newly arrived 15-year-old carpenter J. A. Folger to help build his mill. Folger had come from Nantucket Island with his two older brothers during the California Gold Rush. In the 1850s, kerosene became a cheaper alternative to whale oil, Nantucket's dominant business. Many Nantucket ships were re-purposed to instead bring coffee from South America to San Francisco. After working at Bovee's mill for nearly a year, Folger had saved enough money to buy part of the company, and went to mine for gold. He agreed to carry samples of coffee and spices, taking orders from grocery stores along the way. Upon his return to San Francisco in 1865, Folger became a full partner at Pioneer Steam Coffee and Spice Mills. In 1872, he bought out the other partners and renamed the company J.A. Folger & Co. In 1861, James Folger married. He and his wife had four children, and two of the children worked for the family business. In 1889, Folger died, and his oldest son, James A. Folger II, became president of J.A. Folger & Co at the age of 26. In the 1900s, the company began to grow dramatically due primarily to a salesman named Frank P. Atha.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.